Company intelligence / Profile preview

Savacc

Langhorne, Pennsylvania, United Statesdocs.oracle.com ↗

Ownership: Private
Development stage: Other

Overview

Savara is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare respiratory diseases. Its lead product candidate, molgramostim (trade name MOLBREEVI), is an inhaled recombinant GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The company recently completed a rolling Biologics License Application (BLA) submission to the FDA and anticipates potential Priority Review status due to Breakthrough Therapy designation and promising Phase 3 data[6][7][9]. No products are yet approved.

Therapeutic areas: Rare DiseasesPulmonology
Modalities: ProteinRecombinant proteinBiologic
Industry: Biotech

Partnerships

PARI Pharma GmbH (eFlow® Nebulizer System device partner)[9]

Beyond the preview

Go deeper on Savacc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Savacc.

Explore the full profile